ABCMdb

PMID: 16462814

Rodriguez-Novoa S, Barreiro P, Jimenez-Nacher I, Soriano V
Overview of the pharmacogenetics of HIV therapy.
Pharmacogenomics J. 2006 Jul-Aug;6(4):234-45. Epub 2006 Feb 7., [PubMed]

Sentences

No. Mutations Sentence Comment

87 ABCB1 p.Thr1236Cys ABCB1 p.Thr1236Cys ABCB1 p.Thr1236Cys The percentage of subjects with total bilirubin in the range of jaundice (42.5 mg/dl) was 13% for those with the TA6/TA6 NH COO A61G A3320C T307C T1236C G1199A G2677A,T C3435T G2995T C3396T A2956G •Polymorphism associated with Non-A • Lower EFV plasma levels in T/T genotype • Increased HDL-cholesterol levels in C/C genotype • Low risk of NVP hepatotoxicity in T/T genotype •Polymorphism associated with Protease Inhibitors •Lower NFV plasma levels in T/T genotype •Lower ATV plasma levels in T/T genotype NH2 COO A61G A3320C T307C T1236C G1199A G2677A,T C3435T G2995T C3396T A2956G NH COO- A61G A3320C T307C T1236C G G2677A,T C3435T G2995T C3396T A2956G •Polymorphism associated with Non-Analogues: wer EFV plasma levels in T/T genotype ncreased HDL-cholesterol levels in C/C genotype w risk of NVP hepatotoxicity in T/T genotype •Polymorphism associated with Protease Inhibitors •Lower NFV plasma levels in T/T genotype •Lower ATV plasma levels in T/T genotype Figure 5 Polymorphisms at the MDR1 gene and structure of the P-glycoprotein. Login to comment